BioSpace News Archive

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces a first half trading update for 2019.

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.

Concord Medical Services Holdings Limited, a leading specialty hospital management solutions provider and an operator of the network of radiotherapy and diagnostic imaging centers in China, announced that it will hold an online Q&A session on June 25, 2019 from 2:00PM to 3:00PM, Beijing Time.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Quest Diagnostics Incorporated.

Today, the Chan Zuckerberg Initiative (CZI) announced $68 million in funding to support the Human Cell Atlas and its selection of 38 collaborative science teams to launch CZI’s Seed Networks for a Human Cell Atlas projects.

Tespo, a home healthcare technology company passionate about improving health outcomes through the lens of patient compliance, today announced that Ted Mills, Co-founder and CEO, will present at the Personalized Nutrition Innovation Summit in San Francisco, CA on June 27, 2019 at 2:30 p.m. Pacific Standard Time.

The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

Clear, consistent product labelling helps Canadians make informed decisions about the products they purchase and use.

Surterra Wellness (Surterra), one of the fastest growing health and wellness companies in the United States (U.S.), today announced the close of its acquisition of Massachusetts-based New England Treatment Access (NETA), a premiere, vertically integrated cannabis company

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to SYMDEKO